Compare ALKT & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALKT | ZYME |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2021 | 2022 |
| Metric | ALKT | ZYME |
|---|---|---|
| Price | $20.38 | $28.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $28.57 | ★ $38.90 |
| AVG Volume (30 Days) | ★ 1.3M | 452.0K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $152,159,000.00 | $105,965,000.00 |
| Revenue This Year | $21.85 | $183.10 |
| Revenue Next Year | $16.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 35.68 | ★ 38.87 |
| 52 Week Low | $13.98 | $13.60 |
| 52 Week High | $26.89 | $29.75 |
| Indicator | ALKT | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 63.15 | 70.16 |
| Support Level | $19.57 | $22.10 |
| Resistance Level | $21.05 | $28.49 |
| Average True Range (ATR) | 0.69 | 1.09 |
| MACD | -0.01 | 0.49 |
| Stochastic Oscillator | 72.07 | 99.21 |
Alkami Technology Inc is a cloud-based digital banking solutions provider. The company offers the Alkami Digital Sales & Service Platform, which includes a digital banking platform, onboarding and account opening solutions, and data and marketing tools. The platform enables financial institutions to onboard and engage users, support revenue growth, and improve operational efficiency through a cloud-based, multi-tenant architecture. The company provides services to clients under software-as-a-service arrangements. It derives substantially all of its revenues from SaaS subscription services charged for the use of digital sales and service solutions.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.